Skip to content
‹ Back to IndustriesHealthcare

USP CLASS VI CERTIFICATION

The complexities of medical device bio-compatibility can be difficult to navigate. In this post, we will explain how plastics are classified and tested to ensure patient safety. The U.S. Pharmacopeial Convention (USP) is a nonprofit organization responsible for creating standards for a variety of healthcare elements, including devices and equipment. The USP promotes bio-compatibility for…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The complexities of medical device bio-compatibility can be difficult to navigate. In this post, we will explain how plastics are classified and tested to ensure patient safety.

The U.S. Pharmacopeial Convention (USP) is a nonprofit organization responsible for creating standards for a variety of healthcare elements, including devices and equipment. The USP promotes bio-compatibility for plastics and polymers that come in contact with patient tissue. For these materials, there are six classes, with VI being the most stringent. While the first five classifications are valuable for certain materials, Class VI is the most compatible for medical applications.

USP Class VI – Three Evaluations to Ensure Safety

For the USP Class VI, there are three tests that materials must meet to be deemed safe. There are four standards that these evaluations test: purity, strength, quality and consistency. Here are the three tests explained:

  • Acute Systemic Toxicity measures the toxicity and irritation when a sample of the material is administered orally, placed on the skin or inhaled. It is extracted in up to four solutions: saline, vegetable oil, alcohol saline and polyethylene glycol. The test model is then observed for three days to determine any ill effects.
  • Intracutaneous determines the material’s toxicity and localized irritation when it touches live skin. It is extracted using the same four solutions. Test and control sites are compared to see if there is any significant reaction.
  • Implantation assesses toxicity, infection and irritation of intramuscular These implantations are observed for five to seven days to determine if there is any negative response.

These tests focus on toxicity while evaluating temperature over specific time periods. If a material does meet rigorous USP Class VI standards, then it is likely to be accepted by the FDA and USDA. Class VI testing encompasses any kind of possible applications that include the standard polar and nonpolar extracts required for ISO 10993-12 for completed devices. It’s considered the gold standard for medical-grade raw materials.

The USP Class testing was initially intended for polymers but can also be used to test other materials that encounter patients. The Class labels are meant to represent real-world usage.

EVA from Presco Meets Class VI

EVA (ethylene-vinyl acetate), is a copolymer consisting of ethylene and vinyl acetate. This medical grade film is a soft, clear material that can be RF-welded to create medical solution containers and tubing sets.

With rising concerns regarding the use of PVC in medical applications, EVA has been found to be a suitable alternative for medical use. In fact, for medical bags, EVA is the preferred choice—it has proven track record spanning three decades of wide use in medical device applications, particularly in IV therapy.

Why Choose EVA?

  • 30% lighter than PVC for a better yield and lower shipping costs
  • EVA has better tear and burst strength
  • Exceptional sealing properties
  • Strong impact resistance and cold crack properties
  • Meets all regulatory requirements of the market
  • Bio-compatible as certified with USP Class VI testing
  • No plasticizers or chlorine
  • Printable for fill lines

Pres-Flex EVA is Presco’s first PVC-free manufacturing capability for engineered film. To learn more about USP Class VI certified EVA film from Presco, contact us today. Our team of experienced professionals can guide you through your organization’s unique needs to determine whether this highly-favored PVC alternative is appropriate for your manufacturing processes.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Referral blasts find a bed, not the right bed for the patient

Referral blasts find a bed, not the right bed for the patient

Referral blasts can secure placement quickly but may match patients to any open bed rather than an appropriate one. BedConnect argues for pre-matching on clinical needs, payer participation, and real bed availability so families see viable options, and for judging discharge success at the receiving facility—not at the hospital door.

  • 01Roughly a quarter of Medicare patients discharged to post-acute care return within fourteen days, often because the placement was wrong.
  • 02BedConnect’s approach is to pre-match patients to facilities based on clinical needs, payer participation, and actual bed availability before families see options, as an alternative to broad referral blasts that can result in placements that aren’t a fit.
  • 03Discharge success should be measured at the receiving facility and tracked through readmissions, not at the hospital door.

Sep 29, 2026

Rock Health: $7.4B went into digital health in H1 2026, and 20 rounds took 45%

Rock Health: $7.4B went into digital health in H1 2026, and 20 rounds took 45%

Rock Health: U.S. digital health startups raised $7.4 billion across 244 deals in H1 2026, up from $6.4 billion on 245 deals in H1 2025. The rebound is concentrated. Nineteen companies raised 20 $100 million-plus rounds that captured 45% of capital.

  • 01In H1 2026, 19 companies raised 20 mega-deals of $100 million or more, representing 45% of all capital invested, according to Rock Health.
  • 02According to Rock Health, the firm stopped labeling startups as “AI-enabled,” saying the technology is now too widespread for the label to be meaningful.

Sep 24, 2026

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage. Holland & Knight said hospitals will be eligible for NTAP reimbursement for use of Aidoc’s CARE Body CT Multi-Triage beginning Oct. 1, 2026, with supplemental payments continuing for three years.

  • 01Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage.
  • 02Holland & Knight said CMS approved an NTAP designation for Aidoc’s CARE Body CT Multi-Triage, with hospitals eligible for NTAP reimbursement beginning Oct. 1, 2026, with supplemental payments continuing for three years.

Sep 23, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512